Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
The Johnson & Johnson baby powder once used by a woman with mesothelioma contained millions of asbestos fibers, her attorney told a California jury Monday during opening statements in another trial over the alleged link between the industry titan's products and the carcinogen, while the company countered that sometimes “cancer just happens.”
The Saint Regis Mohawk Tribe and Allergan PLC on Friday asked the Federal Circuit court to reconsider en banc its ruling last month that tribal sovereign immunity doesn’t apply in reviews at the Patent Trial and Appeal Board, which rejected the drugmaker’s attempt to shield patents for its dry-eye medication Restasis by transferring them to the Native American tribe.
Mylan NV and Pfizer Inc. on Monday largely failed to scale down multidistrict litigation over sky-high prices for emergency allergy treatment EpiPen, as a Kansas federal judge mostly refused to throw out wide-ranging consumer claims of anti-competitive shenanigans.
China Biologic Products Holdings Inc. has received a $3.9 billion cash offer from its former chief executive and a consortium of investment firms, according to U.S. Securities and Exchange Commission filings by the company on Monday.
The U.S. Securities and Exchange Commission has dropped its investigation into potential violations of the Foreign Corrupt Practices Act by Chinese vaccine maker Sinovac Biotech Ltd., the company announced on Monday.